Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

New England Journal of Medicine

Volumn 370, Issue 20, 2014, Pages 1879-1888

  Kowdley, Kris V ^a   Gordon, Stuart C ^b   Reddy, K Rajender ^c   Rossaro, Lorenzo ^d   Bernstein, David E ^h   Lawitz, Eric ⁱ   Shiffman, Mitchell L ^k,l   Schiff, Eugene ^o   Ghalib, Reem ^j   Ryan, Michael ^m   Rustgi, Vinod ⁿ   Chojkier, Mario ^e   Herring, Robert ^p   Di Bisceglie, Adrian M ^q   Pockros, Paul J ^f   Subramanian, G Mani ^g   An, Di ^g   Svarovskaia, Evguenia ^g   Hyland, Robert H ^g   Pang, Phillip S ^g   Symonds, William T ^g   McHutchison, John G ^g   Muir, Andrew J ^r   Pound, David ^t   Fried, Michael W ^s   more..

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SCRIPPS CLINIC   (United States)

^g GILEAD SCIENCES   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j Texas Clinical Research Institute   (United States)

^k Bon Secours Health System   (United States)

^l Bon Secours Health System   (United States)

^m Digestive and Liver Disease Specialists   (United States)

ⁿ Metropolitan Liver Diseases   (United States)

^o UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^p Quality Medical Research   (United States)

^q SAINT LOUIS UNIVERSITY   (United States)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY OF NORTH CAROLINA   (United States)

^t Indianapolis Gastroenterology Research Foundation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CELLULITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; IRRITABILITY; LIVER CIRRHOSIS; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; NONCARDIAC CHEST PAIN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RISK FACTOR; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; URIDINE MONOPHOSPHATE; VIRAL LOAD; YOUNG ADULT;

EID: 84900326091     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1402355     Document Type: Article

References (17)

1. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859-61.
2. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press, 2010.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
4. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of precirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72.
5. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(RR-4):1-32.
6. Screening for hepatitis C virus infection in adults: final recommendation statement. Rockville, MD: U.S. Preventive Services Task Force, June 25, 2013 (http://www.uspreventiveservicestaskforce.org/uspstf12/hepc/hepcfinalrs.htm).
7. Aronsohn A, Jensen D. Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology 2014;59:13-5.
8. Sovaldi (sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, December 2013 (http://www.gilead.com/~/media/Files/pdfs/ medicines/liver-disease/sovaldi/sovaldi-pi.pdf).
9. Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24-31.
10. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C: an open-label, randomized, phase 2 trial (LONESTAR). Lancet 2014;383:515-23. [Erratum, Lancet 2014;383:870.]
11. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
14. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
15. Rebetol (ribavirin) capsules: U.S. prescribing information. Whitehouse Station, NJ: Merck, 2003 (https://www.merck.com/product/usa/pi-circulars/r/ rebetol/rebetol-pi.pdf).
16. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-43, e1.
17. Kohli A, Sims Z, Marti M, et al. Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C treatment naive patients: interim results from the NIAID SYNERGY trial. Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. abstract.